Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 1, 2010, Pages 51-58

  Opravil, Milos ^a   Klimkait, Thomas ^b   Louvel, Severine ^c   Wolf, Eva ^d   Battegay, Manuel ^e   Fux, Christoph A ^f   Bernasconi, Enos ^g   Vogel, Martin ^h   Speck, Roberto ^a   Weber, Rainer ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c InPheno AG   (Switzerland)

^d MUC Research GmbH and MVZ Karlsplatz   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Lamivudine; Monotherapy; Replication capacity; Resistance

Indexed keywords

LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MONOTHERAPY; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77951670702     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181bef889     Document Type: Article

References (30)

1. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
2. Hill AM, Smith C. Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment- experienced, HIV-infected patients. HIV Clin Trials. 2007;8:121-131.
3. Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther. 2007;12:1157-1164.
4. Tozzi V, Bellagamba R, Castiglione F, et al. Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART. AIDS Res Hum Retrovir. 2008;24:787-796.
5. Benson CA, Vaida F, Havlir DV, et al. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis. 2006;194:1309-1318.
6. Katlama C, Dominguez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS. 2004;18:217-226.
7. + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296.
8. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 2002;76:11104-11112.
9. Bleiber G, Munoz M, Ciuffi A, et al. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol. 2001;75:3291-3300.
10. Deval J, White KL, Miller MD, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem. 2004;279:509-516.
11. Zennou V, Mammano F, Paulous S, et al. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol. 1998;72:3300-3306.
12. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795-803.
13. Van Laethem K, De Luca A, Antinori A, et al. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther. 2002;7:123-129.
14. Sune C, Brennan L, Stover DR, et al. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure. Clin Microbiol Infect. 2004;10:119-126.
15. Holguin A, Sune C, Hamy F, et al. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol. 2006;36:264-271.
16. Louvel S, Battegay M, Vernazza P, et al. Detection of drug-resistant HIV minorities in clinical specimens and therapy failure. HIV Med. 2008;9: 133-141.
17. Gottlinger HG, Dorfman T, Sodroski JG, et al. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA. 1991;88:3195-3199.
18. Yu XF, Dawson L, Tian CJ, et al. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J Virol. 1998;72:3412-3417.
19. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003;349:837-846. (Pubitemid 37025403)
20. Walmsley SL, Thorne A, Loutfy MR, et al. A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164). J Acquir Immune Defic Syndr. 2007;45:418-425.
21. Skiest DJ, Su Z, Havlir DV, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis. 2007;195:1426-1436.
22. Gianotti N, Tiberi S, Menzo S, et al. HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. J Med Virol. 2008;80:201-208.
23. + Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145-1155.
24. Petrella M, Oliveira M, Moisi D, et al. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob Agents Chemother. 2004;48:4189-4194.
25. Fox Z, Dragsted UB, Gerstoft J, et al. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther. 2006; 11:761-770.
26. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005;192:1537-1544.
27. Sturmer M, Staszewski S, Doerr HW. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antivir Ther. 2007;12:695-703.
28. Abadi J, Sprecher E, Rosenberg MG, et al. Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children. J Acquir Immune Defic Syndr. 2006; 41:298-303.
29. Llibre JM, Bonjoch A, Iribarren J, et al. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. HIV Med. 2008;9:508-513.
30. Launay O, Duval X, Dalban C, et al. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109). Antivir Ther. 2006;11:889-899.